Pharmaceutical News

RSS

Sport Endurance develops new formula that enables safe consumption of Creatine

Sport Endurance, Inc, a health supplement company, has developed a revolutionary formula that enables the safe consumption of Creatine, a proven muscle-building and performance enhancing dietary supplement.

17 Aug 2010

FDA considers dropping Avastin approval, approves five-day emergency contraception pill

The Food and Drug Administration is considering revoking its approval of a last-ditch breast cancer drug over the debate on "medical spending and effectiveness that flared during the battle over health-care reform," The Washington Post reports. "The [FDA] is reviewing the recommendation of influential scientific advisers to revoke authorization of the drug to treat metastatic breast cancer.

17 Aug 2010

FDA issues Proposal to Withdraw Marketing Approval for orthostatic hypotension drug midodrine hydrochloride

The U.S. Food and Drug Administration today proposed to withdraw approval of the drug midodrine hydrochloride, used to treat the low blood pressure condition orthostatic hypotension, because required post-approval studies that verify the clinical benefit of the drug have not been done.

17 Aug 2010

Ill effects of methamphetamine

On the street it's known as meth, speed, ice, chalk, crank, fire, glass or crystal. Methamphetamine is a highly addictive drug that wreaks havoc on the entire body, including the user's oral health. Approximately 10 million Americans have tried methamphetamine, while more than 1.4 million are habitual users.

17 Aug 2010

Global vaccine sales up 16% in 2009, report says

Global vaccine sales "grew by a healthy 16 percent last year, when sales shot up to $22.1 billion, healthcare market research publisher Kalorama Information reported Friday," according to the Associated Press. Kalorama is also forecasting sales "will rise at a compound annual rate of 9.7 percent during the next five years," (Johnson, 8/14).

17 Aug 2010

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

17 Aug 2010

Amphetamine abuse associated with increased risk of aortic dissection

Young adults who abuse amphetamines may be at greater risk of suffering a tear in the main artery leading from the heart, UT Southwestern Medical Center researchers have found.

16 Aug 2010

CVS/Pharmacy opens new store in Omaha

CVS/pharmacy celebrated its entry into the Omaha market today with a grand opening at one of its two new stores in the city of Omaha. Joining CVS officials at the ceremony were The Honorable Jim Suttle, Mayor of Omaha and City Councilmember Thomas Mulligan, District #7.

16 Aug 2010

Jiangbo receives Shandong FDA approval to market Felodipine SR tablets

Jiangbo Pharmaceuticals, Inc., today announced that the Company received approval from the Shandong Food and Drug Administration to start the sales of Felodipine sustained release tablets.

16 Aug 2010

Cortex second-quarter net loss decreases to $0.04 per share

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $2,454,000, or $0.04 per share, for the quarter ended June 30, 2010, compared with a net loss applicable to common stock of approximately $2,778,000, or $0.06 per share, for the corresponding prior year period.

16 Aug 2010

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222. This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

16 Aug 2010

Green Cross receives KFDA approval to manufacture, market i.v. peramivir: BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. announced that its partner, Green Cross Corporation has received marketing and manufacturing approval from KFDA for intravenous peramivir to treat patients with influenza A & B viruses, including pandemic H1N1 and avian influenza. Green Cross Corp. intends to launch peramivir under the commercial name PeramiFlu in South Korea.

16 Aug 2010

Cangene to focus commercialization efforts on key markets

Cangene Corporation today reports that it will further focus its commercialization efforts on key markets for its products in the near term. Cangene acquired the U.S. commercialization rights to HepaGam B(R) (Hepatitis B Immune Globulin Intravenous (Human)) in October 2009 and soon after began building a U.S. sales force.

16 Aug 2010

Genentech asserts SPC non-infringement of products in Europe, seeks response from PDL

PDL BioPharma, Inc. announced today it has received a facsimile letter from Genentech asserting that Avastin, Herceptin, Lucentis and Xolair (the Genentech Products) do not infringe supplementary protection certificates granted by various countries in Europe to PDL and is seeking a response from PDL to these assertions.

16 Aug 2010

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Pharmaceutical research and biotechnology companies in New Jersey, California, New York and North Carolina are responsible for 192 of the 313 medicines in development today to treat mental illnesses, a new survey shows.

16 Aug 2010

CTI announces EMEA's validation of expanded PIP for pixantrone

Cell Therapeutics, Inc. announced today that it has received notice that the European Medicines Agency has validated the expanded Pediatric Investigation Plan that CTI filed in July for pixantrone for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).

16 Aug 2010

R-Tech Ueno, Sucampo Pharmaceuticals request arbitration against Takeda Pharmaceutical

R-Tech Ueno supplies Amitiza (TM) Capsules to Takeda pursuant to agreements with Takeda and Sucampo. On March 12, 2010, Sucampo submitted for filing with the International Court of Arbitration, International Chamber of Commerce, a Request for Arbitration against Takeda. In that Request, Sucampo claimed that Takeda has violated the provisions of the October 29, 2004, Collaboration and License Agreement between Sucampo and Takeda and other applicable duties, and that Takeda's violations have injured Sucampo. Sucampo requested all appropriate relief, including termination of the agreements, damages remedy and so on.

16 Aug 2010

Watson to launch ella emergency contraceptive in fourth-quarter 2010

Watson Pharmaceuticals, Inc., today announced that it intends to launch ella® (ulipristal acetate), a novel oral emergency contraceptive, in the fourth quarter of 2010. Watson's announcement follows the approval of ella® by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post-unprotected intercourse (UPI) or contraceptive failure.

16 Aug 2010

US WorldMeds announces acquisition of Solstice Neurosciences for $35M

US WorldMeds, LLC, a Kentucky-based specialty pharmaceutical company that develops unique products to address unmet medical needs, today announced it has acquired Solstice Neurosciences, Inc. for $35 million. The acquisition expands US WorldMeds' operations, adds to the company's growing portfolio of products and enhances the company's ability to create and deliver high-quality specialty pharmaceutical products to its targeted global markets.

16 Aug 2010

FDA's labeling of Ella as 'Emergency Contraceptive' misleading, says FRC

Today the Food and Drug Administration (FDA) approved Ella, a drug that can cause abortions but is misleadingly labeled as a more effective "Emergency Contraceptive."

16 Aug 2010

Pharmaceutical News

Sport Endurance develops new formula that enables safe consumption of Creatine

FDA considers dropping Avastin approval, approves five-day emergency contraception pill

FDA issues Proposal to Withdraw Marketing Approval for orthostatic hypotension drug midodrine hydrochloride

Ill effects of methamphetamine

Global vaccine sales up 16% in 2009, report says

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Amphetamine abuse associated with increased risk of aortic dissection

CVS/Pharmacy opens new store in Omaha

Jiangbo receives Shandong FDA approval to market Felodipine SR tablets

Cortex second-quarter net loss decreases to $0.04 per share

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

Green Cross receives KFDA approval to manufacture, market i.v. peramivir: BioCryst Pharmaceuticals

Cangene to focus commercialization efforts on key markets

Genentech asserts SPC non-infringement of products in Europe, seeks response from PDL

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

CTI announces EMEA's validation of expanded PIP for pixantrone

R-Tech Ueno, Sucampo Pharmaceuticals request arbitration against Takeda Pharmaceutical

Watson to launch ella emergency contraceptive in fourth-quarter 2010

US WorldMeds announces acquisition of Solstice Neurosciences for $35M

FDA's labeling of Ella as 'Emergency Contraceptive' misleading, says FRC

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News